Replies to post #296883 on NorthWest Biotherapeutics Inc (NWBO)

[evanstony]

And yes, $$$$$$ may be sooner than some naysayers would have us believe

Made me think of two things... First you could be very right and second a favorite axiom from the technical chart crowd... "The longer the base the higher the space"...

Technicals and Fundamentals do have their perspective biases but as a gambler of sorts the psychology of the buyer in the next technical move from this long base will leave the Fundamental crowd far behind with a series of doubles and triples that will be off the charts and fundamentally impossible to believe!!

[exwannabe]

This entire subject is total nonsense. Direct and -L are very different. About as different as any two DC vaccines can be.

The Indian DC vaccine might be considered "essentially the same". The UCLA manufactured version might be "essentially the same".

Their have been hundreds of DC vaccines in trials. When categorizing them, the first thing to look at is what antigens are used in the process. -L uses the entire tumor. Direct uses none.

Nothing magic happens if -L gets approved to make things go faster. Well, more money for sure hekps. But still need real trials.

Even label expansions take P3 trials. AMRN's Vascepa was first approved 8 years ago but only for very high trig levels. It took them over 7 years to get a label expansion to high (but more moderate) trig levels. And Optune was first approved for rGBM about a decade ago. Then got their label expansion to nGBM several years back. They still have years to go for the big money labels.

And these are the exact same product, not "essentially the same".

It takes time and money.